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Survival, clinical, immunological and hematological out-
comes of antiretroviral therapy among HIV-infected
children attending a public clinic in Kinshasa, Democratic
Republic of Congo
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Edmonds1, F. Behets1, G. the SARA team2
1 Gillings School of Global Public Health, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA
2 Ecole de Santé Publique, University of Kinshasa, Demo-
cratic Republic of Congo, Kinshasa, Congo, Democratic
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3 Kalembe Lembe Pediatric Hospital, Kinshasa, Democratic
Republic of Congo, Kinshasa, Congo, Democratic Republic
of
Background: To assess the mortality, immunological,
hematological, and clinical outcomes of children initiating
antiretroviral therapy (ART) during the ﬁrst 5 years (Novem-
ber 2004 — October 2009) of a standardized HIV care and
treatment program at the Kalembe-Lembe pediatric hospital
in Kinshasa, DRC.
Methods: Retrospective analysis of routine clinical data
from a cohort of 603 HIV-infected children) 17 years of age
at ART initiation.
Results: Children initiated ART at a median age of 6.4
[interquartile range 3.2—10.5] years. At ART initiation,
27.1% were on treatment for tuberculosis, 54.6% were in
WHO stage III&IV, 52.8% had < 10 g/dL hemoglobin, 63.0%
had a CD4%) 15% (severe immunosuppression), 39.6% had
a weight-for-age Z score (WAZ)) -3 (severe underweight),
and 9.8% had previously received antiretrovirals. The ﬁrst
line regimens included stavudine or zidovudine, lamuvi-
dine, and nevirapine or efavirenz. During 1409.8 child-years
of follow-up (median follow-up, 28.7 months), 61 children
died: 38 during the ﬁrst 90 days of treatment (early mortal-
ity rate, 28.0/100 child-years; 95% Conﬁdence Interval (CI),
20.4—38.4) and 23 after 90 days (latemortality rate, 1.6/100
child-years; 95% CI, 1.9—2.5). The mean CD4% and WAZ rose
rapidly from 11.6% and -2.57 at baseline to 25.0% and -1.92
at 12 months before stabilizing above 28.0% and around -
1.80 between 18 and 48 months, respectively. The mean
height-for-age Z scores (HAZ) and hemoglobin increased
almost linearly from -2.23 and 9.8 g/dL at baseline to −1.78
and 10.8 g/dL at 12 months to -1.23 and 12.0 g/dL at 48
months, respectively. Children under two years of age at ART
initiation had greater and more sustained gains in weight,
height, CD4% and hemoglobin compared to children who
started ARTwhen at least two years of age (p < 0.01, p < 0.01,
p = 0.01, p < 0.01, respectively).
Conclusion: Despite late presentation in our clinic, good
clinical, immunological, and hematologic outcomes were
obtained within the ﬁrst 12 months and maintained through
48months of ART among children who survived the ﬁrst three
months. The high early mortality rate reﬂects obstacles to
health seeking behavior, early HIV diagnosis, and access to








pparent virologic failures and blips in a suburban HIV
linic caused by laboratory errors in a commercial HIV-1
NA PCR assay
. Cariello ∗, T. Treadwell
MetroWest Medical Center, Framingham, MA, USA
Background: The use of commercial assays for quantiﬁca-
ion of viral RNA is a cornerstone in management of patients
ith HIV infection. We recently observed an increase in blips
nd apparent virologic failure not explained by poor adher-
nce or resistance and that resolved when our clinic changed
aboratories.
Methods: We retrospectively collected data on patients
ho were receiving highly active antiretroviral therapy
HAART) from October 2004 until June 2006 and who had
ne or more HIV-1 plasma viral load (VL) > 1,000 copies/mL.
e excluded patients who had interruptions in therapy
r had known poor adherence to clinic visits or medica-
ions.
Results: Our clinic changed our reference laboratory in
ecember 2005. In the previous 15 months, 38 patients on
AART had at least one VL > 1,000 copies/mL. Six patients
ad at least one VL > 10,000 copies/mL and 24 patients
ad more than 2 determinations > 1,000 copies/mL. In the
months following the lab change, 37/38 patients had
L < 400, 21/38 < 50, and only one patient had a VL >
00 copies/mL. One year later, 36/38 had no detectable
lasma viral RNA. All patients had stable CD4 lymphocyte
ounts (mean = 636 cells/mm3). Twenty-one patients had at
east one genotype during this period; no new mutations we
ound.
Conclusion: We believe that systematic errors in a com-
ercial laboratory contributed to apparent virologic failures
nd blips in this small group of patients.
oi:10.1016/j.ijid.2010.02.2038
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ntiretroviral resistance-associated mutations and
enomic diversity in reverse transcriptase and protease
ene among drug-naïve patients
. Saini 1,∗, P. Bhalla1, U.K. Baveja2, S.T. Pasha2, R. Dewan3
Maulana Azad Medical College, New Delhi, India
National Institute of Communicable Diseases, Delhi, India
Maulana Azad Medical College, Delhi, India
Background: Antiretroviral drugs (ARV) are being pro-
ided by Govt. of India since 2004 under 3 by 5 initiative
ed by WHO-UNAIDS. Despite wide spread use of ARV, little
nformation is available on the prevalence of transmitted
esistance-associated mutations in HIV-1, particularly from
orth India. The present study was designed for molec-
lar characterization of HIV-1 and identiﬁcation of ARV
esistance- associated mutations and naturally occurring
enotypic variation in reverse transcriptase (RT) and pro-
ease region of pol gene of HIV-1.
Methods: Seventy ARV drug-naïve HIV-1 sero-reactive
atients, newly registered in ART clinic of Lok Nayak Hos-

































































































a pandemic situation, the rapid virucidal activity provides
a decided advantage in reducing Inﬂuenza transmission via
hand contact.248 14
nformed consent. Plasma HIV-1 RNA levels were estimated
y Amplicor HIV-1 Monitor test V 1.5 (Roche Diagnostics).
IV-1 pol gene, enconsisting protease region (codons;1-99)
nd RT region (codons;1-232 to 1-239) was reverse tran-
cribed, followed by nested PCR with self designed primers.
he PCR product was sequenced with an ABI PRISM 3100
enetic analyzer system.
Results: The median HIV-1 RNA levels were log10 4.6
opies/ml (IQR; 4.2-5.3). All patients were found to be
nfected with HIV-1 subtype C. Only one (1.4%) study
equence harbored resistance-associated mutations in RT
egion, showing NRTI resistance mutation (M184I). No muta-
ion at major resistance positions in protease region was
etected. High rate of polymorphisms were observed at
odons; 35, 39, 40, 48, 60, 121, 122, 123, 135, 166, 173,
74, 177, 185, 200, 204, 206, 207, 208, 211, 216, 217, 233
239 in RT gene and 12, 15, 18, 19, 36, 38, 41, 63, 69, 70,
9 & 93 in protease gene.
Conclusion: The overall prevalence of transmitted
esistance-associated mutations was found to be 1.4%, lower
han the alert cut off of 5% deﬁned by WHO. HIV-1 sub-
ype C exhibited enormous polymorphism in RT and protease
egions of pol gene as compared to subtype B.
oi:10.1016/j.ijid.2010.02.2039
nfection Control, Nosocomial Infections and Critical
are (Poster Presentation)
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linical, radiological and microbiological corroboration to
ssess the role of endotracheal aspirate in diagnosing
entilator-associated pneumonia in an intensive care unit
f a tertiary care hospital, India
. Mukhopadhyay ∗, S. Krishna, A. Shenoy, K. Prakashini
Kasurba Medical College, Manipal, India
Background: Early and accurate diagnosis and follow up
f VAP varies considerably with the clinical, radiological and
icrobiological criteria employed.
Methods: This study was aimed to correlate clinico-
adiological ﬁndings with microscopy and quantitative
ulture of consecutive ETA from 50 mechanically ventilated
atients along with the antibiogram and risk factor assess-
ent.
Results: The prospective observational study in MICU
evealed the incidence of VAP to be 42% with a rate of
16/1000 ventilator days. 8 had early onset and 13 late
nset VAP, with no age or sex signiﬁcant preponderance. The
ttributable mortality rate was 61.9% which rose with dura-
ion of stay. The important independent risk factors were
ulti-organ failure, reintubation and pleural effusion. The
ost commonly isolated organisms were multidrug resistant
cinetobacter baumannii (76%) and Pseudomonas aerugi-
osa (42%). All enterobacterial isolates were ESBL producing
nd all S. aureus isolates were methicillin resistant. In 66%,
olonization on day 1 resulted in development of VAP on day
. Gram stain ﬁndings had a signiﬁcant correlation with the
uantitative culture of ETA, which by itself showed a signif-
cantly progressive increase in speciﬁcity in diagnosing VAP
n day 7. The strength of association between CPIS scoring,
dternational Congress on Infectious Diseases (ICID) Abstracts
he microbiological ﬁndings and the clinical diagnosis was
ound to be strong.
Conclusion: This study emphasizes that Gram stain and
uantitative culture of ETA can be considered useful for the
iagnosis of VAP and a combined clinical, radiological and
icrobiological approach can be successful in the manage-
ent and further follow up of VAP.
oi:10.1016/j.ijid.2010.02.2040
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irucidal efﬁcacy of topical antiseptics versus a novel
train of Inﬂuenza H1N1
. Dzyakanava1,∗, K. Burningham2, J. Stahl3
BioScience Laboratories, Bozeman, MT, USA
Bioscience Laboratories, Bozeman, MT, USA
3M Company, Saint Paul, MN, USA
Background: On April 11, 2009 the WHO raised the epi-
emic alert to Phase 6 and declared a pandemic of novel
nﬂuenza H1N1. During the impending inﬂuenza season, the
umber of ‘‘swine’’ inﬂuenza cases is expected to increase,
mphasizing the importance to public health of contact and
espiratory hygiene. This study evaluated the susceptibility
f Inﬂuenza H1N1 A/California/04/2009 strain to three topi-
al sanitizing products, designed for application in a variety
f public and healthcare settings.
Methods: ASTM E 1052-96, Standard Test Method for Efﬁ-
acy of Antimicrobial Agents against Viruses in Suspension,
as used to evaluate a non-medicated soap and three topical
ntiseptics: AvagardTM Surgical and Healthcare Personnel
and Antiseptic (1% Chlorhexidine Gluconate, 61% Ethanol);
vagardÔ Foam Instant Hand Antiseptic (62% Ethanol); and
vagardÔ D Instant Hand Antiseptic (61% Ethanol). All
roducts were tested at a 90% (v/v) concentration versus
nﬂuenza H1N1 A/California/04/2009 strain with exposures
f 30 seconds, 1minute, and 2minutes. Viral titers were cal-
ulated using the Spearman- Kärber Method.
Results: All products signiﬁcantly reduced infectivity
f the epidemic strain of Inﬂuenza H1N1. AvagardTM (1%
hlorhexidine Gluconate, 61% Ethanol) and AvagardTM D
61% Ethanol) produced 5.25 log10 (>99.999%) reduction
fter 30 second exposure, as well as after 1 and 2minute
xposures. AvagardÔ Foam (62% Ethanol) reduced the viral
opulation by 4.25 log10 (>99.99%) after 30 second, 1, and
minute exposures. Testing performed on non-medicated
oap revealed low virucidal efﬁcacy after short-term expo-
ures: 2.50 log10 (99.68%) reduction after 30 second and
minute exposures.
Conclusion: Signiﬁcant reduction (>99.99%) in the pop-
lation of A/California/04/2009 strain was achieved after
0 second exposures of the virus to the hand sanitizers. Inoi:10.1016/j.ijid.2010.02.2041
